SCHEMBL245190

SCHEMBL245190

C[C@@H](C(=O)O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 4/20 0.69
CXCR1 P25024 3/20 0.68
AKR1C3 P42330 10/20 0.47
PTGS2 P35354 9/20 0.47
AKR1C2 P52895 9/20 0.47
PTGS1 P23219 6/20 0.47
TSHR P16473 2/20 0.47
SLC22A6 Q4U2R8 2/20 0.47
CDC42 P60953 1/20 0.47
RAC1 P63000 1/20 0.47
CYP1A2 P05177 1/20 0.47
LMNA P02545 2/20 0.45
CYP2C9 P11712 2/20 0.45
ALB P02768 1/20 0.45
ESR1 P03372 1/20 0.45
ALOX5 P09917 1/20 0.45
RARB P10826 1/20 0.45
ADRB3 P13945 1/20 0.45
NFKB1 P19838 1/20 0.45
HTR2A P28223 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345636 1.00 CXCR2 (0.69) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL1820095 1.00 CXCR2 (0.69) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL4414662 0.87 CXCR2 (0.66) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL4747670 0.87 CXCR2 (0.66) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL252024 0.87 CXCR2 (0.66) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL246051 0.87 CXCR2 (0.66) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL18770103 0.86 AKR1C3 (0.64) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL1822574 0.86 CXCR2 (0.68) CXCR2CXCR1AKR1C3PTGS2AKR1C2
SCHEMBL251658 0.84 CXCR2 (0.75) CXCR2CXCR1
SCHEMBL250803 0.84 CXCR2 (0.75) CXCR2CXCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063242-B2 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion DOMPE PHA.R.MA S.P.A. (IT) 2011-11-22 US claimed
US-8039656-B2 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them DOMPÉ FARMACEUTICI S.P.A. (IT) 2011-10-18 US claimed
EP-1455773-B1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-04 EP claimed
EP-1776336-B1 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-09-30 EP claimed
US-20090203740-A1 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A (IT) 2009-08-13 US claimed
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPÉ FARMACEUTICI S.P.A. (IT) 2005-02-17 US claimed
EP-1455773-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2004-09-15 EP claimed
WO-2003043625-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2003-05-30 WO claimed
EP-4686469-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES Dompé farmaceutici SpA (IT) 2026-02-04 EP disclosed
EP-4686472-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE Dompé farmaceutici SpA (IT) 2026-02-04 EP disclosed
EP-4678171-A1 SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompé farmaceutici SpA (IT) 2026-01-14 EP disclosed
EP-4646193-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompé farmaceutici S.p.A. (IT) 2025-11-12 EP disclosed
EP-4563594-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF TUMORS WITH LOW STROMAL CAV1 LEVELS Dompe' Farmaceutici SpA (IT) 2025-06-04 EP disclosed
WO-2024146918-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID DOMPE' FARMACEUTICI SPA (IT) 2024-07-11 WO disclosed
CN-101360706-A (R) -arylalkylamino derivatives and pharmaceutical compositions thereof DOMPE PHA R MA SPA RES & MFG (IT) 2009-02-04 CN disclosed
EP-1776336-A2 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2007-04-25 EP disclosed
WO-2005090295-A2 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA S.P.A. (IT) 2005-09-29 WO disclosed
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPÉ FARMACEUTICI S.P.A. (IT) 2005-02-17 US disclosed
EP-1455773-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2004-09-15 EP disclosed
WO-2003043625-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203740-A1 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them CXCR2, CXCR3, MMP8 CXCR2 1/4885CXCR1 4/4885AKR1C3 1026/4885
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them CXCR2, FPR1, CCR2 CXCR2 1/4885CXCR1 8/4885AKR1C3 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.